An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Background. Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. Methods. We assessed the relative risk for all treatment-related adv...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Hye Duck Choi (Tekijä), Ji Hae Kim (Tekijä)
Aineistotyyppi: Kirja
Julkaistu: Hindawi-Wiley, 2023-01-01T00:00:00Z.
Aiheet:
Linkit:Connect to this object online.
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Internet

Connect to this object online.

3rd Floor Main Library

Saatavuus: 3rd Floor Main Library
Hyllypaikka: A1234.567
Nide 1 Saatavissa